A phase 2 study of XL999 administered intravenously to subjects with metastatic colorectal cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2015
At a glance
- Drugs XL 999 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Symphony Evolution
- 23 Feb 2010 Actual patient number (17) added as reported by ClinicalTrials.gov.
- 23 Feb 2010 Planned end date (1 Feb 2007) as reported by ClinicalTrials.gov.
- 31 Jan 2006 New trial record.